Navigation Links
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
Date:11/2/2011

NATICK, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export (SINE) for various cancers.  The Company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

Michael Kauffman, MD, PhD, Karyopharm's CEO, remarked, "This funding shows the confidence our investors have in our progress and platform. With these additional resources, we are able to move our oral clinical SINE compound for oncology into Phase I studies in both hematologic and solid tumor malignancies. The oral bioavailability and preliminary tolerability of the compounds allow us to investigate these agents for indications outside of cancer, including autoimmune, inflammatory and viral disorders.  We look forward to bringing the first SINE therapeutic to patients with cancer in the coming year."

Karyopharm is the leader in the development of nuclear transport modulators for the treatment of cancer, autoimmune, dermatologic, and viral diseases. These SINEs act by forcing the nuclear localization of major tumor suppressor and growth regulatory proteins, causing selective death of cancer cells while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown activity in a variety of animal models.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of small molecule modulators of nuclear transport.  The Company was founded by Drs. Sharon Shacham, Michael Kauffman, Giulio Draetta and Ronald DePinho in 2008.  Karyopharm completed a $20M Series A financing in October, 2010. The Company has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. By inhibiting the nuclear export of tumor suppressor proteins, Karyopharm's drug candidates force the activation of the cell's key tumor suppressor and anti-inflammatory pathways including p53, p21, pRB, FoxO, and the inhibitor of NF-kB (i.e., IkB).  Karyopharm anticipates entering the clinic in 2012 with its first oral SINE compound for the treatment of various cancers.  The Company is also evaluating the use of SINE in autoimmune, viral and dermatologic disorders.  Karyopharm Therapeutics is located in Natick, Massachusetts.

Contact: Michael Kauffman, +1-508-975-4821, mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
6. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
7. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
8. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
9. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
10. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Alex,s Lemonade Stand Foundation (ALSF), a ... will open a state-of-the-art bioinformatics lab, using ,big data, ... announcement comes as Liz Scott , co-executive director ... Moonshot Summit in Washington, D.C. , ... participant and advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
Breaking Biology News(10 mins):